Please login to the form below
HER-2 breast cancer
This page shows the latest HER-2 breast cancer news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca's Enhertu receives FDA grant for priority review
The approval is based on results from the DESTINY-Breast03 trial which showed a significant risk reduction of unresectable or metastatic HER-2 positive breast cancer progression. ... For patients diagnosed with HER2-positive metastatic breast cancer,
Latest news
-
EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug
Antibody drug conjugate gained approval in US in December. The European Medicines Agency (EMA) has accelerated the assessment of Daiichi Sankyo and AstraZeneca’s HER2-positive breast cancer candidate, fast-tracking ... The drug presents a new challenge
-
Novartis highlights emerging assets and late-stage pipeline at R&D day
Lu-PSMA-617, a radioligand therapy for prostate cancer which has phase 3 readouts due in the near future. ... It also has plans to expand wet AMD therapy Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments Piqray (alpelisib) and
-
Pfizer's Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund
cancer. Ibrance (palbociclib), in combination with fluvestrant has been approved for use via the Cancer Drugs Fund in women with previously treated, HR positive and HER2 negative metastatic breast cancer. ... It originally scored approval in the EU in
-
Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal
early breast cancer in the neo-adjuvant and adjuvant setting. ... Additionally Herzuma was also recommended for patients with metastatic breast cancer and metastatic gastric cancer in adults.
-
FDA backs earlier use of Lilly’s breast cancer drug Verzenio
negative metastatic breast cancer,” said Joyce O'Shaughnessy, chair of the breast cancer research programme for Baylor University Medical Center, in a press release. ... This information will help inform treatment decisions for each patient, which can
More from news
Approximately 1 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Putting the ovation into innovation: trends from ESMO
The real value of real-world evidence in advanced breast cancer. Real-world evidence (RWE) is playing an ever- increasing role in treatment decision-making, in all forms of cancer. ... the ESMO 2020 Congress combination with endocrine therapy and
-
Pharma deals during October 2014
Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in milestones for ADU 214 in the treatment of lung cancer. ... in breast and gastric cancer.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
PMHub
Anthem PR
With a rare strength in media and influencer relations, Anthem’s award-winning team offers a fresh approach to health PR...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
